{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ZD6474+%28Vandetanib%29&page=2",
    "query": {
      "intervention": "ZD6474 (Vandetanib)",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 49,
    "total_pages": 5,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ZD6474+%28Vandetanib%29&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ZD6474+%28Vandetanib%29&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-07T00:56:46.291Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00822887",
      "title": "Dose Escalation Study of Vandetanib With Hypofractionated Stereotactic Radiotherapy in Recurrent Malignant Gliomas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Malignant Gliomas"
      ],
      "interventions": [
        {
          "name": "Vandetanib",
          "type": "DRUG"
        },
        {
          "name": "Fractionated Stereotactic Radiotherapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 13,
      "start_date": "2007-03",
      "completion_date": "2011-01",
      "has_results": false,
      "last_update_posted_date": "2013-06-26",
      "last_synced_at": "2026-10-07T00:56:46.291Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00822887"
    },
    {
      "nct_id": "NCT00047788",
      "title": "Efficacy Study of ZD6474 to Treat Multiple Myeloma Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "ZD6474",
          "type": "DRUG"
        },
        {
          "name": "VEGF-receptor tyrosine kinase (KDR)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genzyme, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2002-10",
      "completion_date": "2004-05",
      "has_results": false,
      "last_update_posted_date": "2016-08-24",
      "last_synced_at": "2026-10-07T00:56:46.291Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00047788"
    },
    {
      "nct_id": "NCT00404924",
      "title": "ZD6474 (ZACTIMA™) Phase III Study in EGFR Failures",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Non-Small-Cell Lung Carcinoma"
      ],
      "interventions": [
        {
          "name": "ZD6474 (vandetanib)",
          "type": "DRUG"
        },
        {
          "name": "Best Supportive Care",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Genzyme, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1140,
      "start_date": "2006-11",
      "completion_date": "2014-11",
      "has_results": true,
      "last_update_posted_date": "2016-09-30",
      "last_synced_at": "2026-10-07T00:56:46.291Z",
      "location_count": 2,
      "location_summary": "Tucson, Arizona • Germantown, Tennessee",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Germantown",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00404924"
    },
    {
      "nct_id": "NCT00613223",
      "title": "Ph I Dose Escalation Trial of Vandetanib in Combo w Etoposide for Malignant Gliomas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Gliosarcoma",
        "Glioblastoma"
      ],
      "interventions": [
        {
          "name": "Vandetanib and Etoposide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Annick Desjardins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 49,
      "start_date": "2008-02",
      "completion_date": "2011-05",
      "has_results": false,
      "last_update_posted_date": "2013-02-20",
      "last_synced_at": "2026-10-07T00:56:46.291Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00613223"
    },
    {
      "nct_id": "NCT00566995",
      "title": "Phase II Study of Vandetanib in Individuals With Kidney Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Renal Cancer",
        "Von Hippel Lindau"
      ],
      "interventions": [
        {
          "name": "ZACTIMA (Vandetanib) (ZD6474)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 37,
      "start_date": "2008-02-07",
      "completion_date": "2015-03",
      "has_results": true,
      "last_update_posted_date": "2018-10-30",
      "last_synced_at": "2026-10-07T00:56:46.291Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00566995"
    },
    {
      "nct_id": "NCT00047840",
      "title": "This Study is to Assess the Efficacy and Safety of ZD6474 in Subjects With Non-small Cell Lung Cancer.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer (NSCLC, Locally Advanced or Metastatic, Second-line"
      ],
      "interventions": [
        {
          "name": "ZD6474",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genzyme, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 129,
      "start_date": "2002-10",
      "completion_date": "2006-09",
      "has_results": false,
      "last_update_posted_date": "2016-08-25",
      "last_synced_at": "2026-10-07T00:56:46.291Z",
      "location_count": 16,
      "location_summary": "Los Angeles, California • Jacksonville, Florida • Atlanta, Georgia + 13 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00047840"
    },
    {
      "nct_id": "NCT00880334",
      "title": "Randomized Study of Docetaxel +/- Vandetanib in Metastatic TCC",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Transitional Cell Carcinoma",
        "Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "vandetanib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 149,
      "start_date": "2006-09",
      "completion_date": "2015-05",
      "has_results": true,
      "last_update_posted_date": "2018-09-18",
      "last_synced_at": "2026-10-07T00:56:46.291Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00880334"
    },
    {
      "nct_id": "NCT00410761",
      "title": "An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Thyroid Cancer"
      ],
      "interventions": [
        {
          "name": "ZD6474 (Vandetanib)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genzyme, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 331,
      "start_date": "2006-11-23",
      "completion_date": "2024-07-26",
      "has_results": true,
      "last_update_posted_date": "2025-09-24",
      "last_synced_at": "2026-10-07T00:56:46.291Z",
      "location_count": 32,
      "location_summary": "Little Rock, Arkansas • San Francisco, California • Aurora, Colorado + 13 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00410761"
    },
    {
      "nct_id": "NCT00402896",
      "title": "Malignant Pleural Effusion With ZD6474",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lung Cancer",
        "Pleural Effusion"
      ],
      "interventions": [
        {
          "name": "ZD6474",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 28,
      "start_date": "2006-10",
      "completion_date": "2014-06",
      "has_results": true,
      "last_update_posted_date": "2016-03-09",
      "last_synced_at": "2026-10-07T00:56:46.291Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00402896"
    },
    {
      "nct_id": "NCT01372813",
      "title": "Vandetanib to Treat Advanced Kidney Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Clear Cell Renal Carcinoma"
      ],
      "interventions": [
        {
          "name": "vandetanib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3,
      "start_date": "2007-12",
      "completion_date": "2010-06",
      "has_results": true,
      "last_update_posted_date": "2015-10-23",
      "last_synced_at": "2026-10-07T00:56:46.291Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01372813"
    }
  ]
}